Vaxcyte says VAX-31 pneumococcal vaccine met primary endpoints in Phase 3 OPUS-1 trial
Vaxcyte said its 31-valent pneumococcal vaccine VAX-31 hit the primary endpoints in the Phase 3 OPUS-1 trial in adults, positioning it against Pfizer's Prevnar and Merck's Capvaxive.
1 / 2
The story, neutrally told
Centre · 1Vaxcyte said on Monday 5 October that its experimental pneumococcal vaccine VAX-31 hit the primary endpoints in a Phase 3 clinical trial. STATN “Vaxcyte said Monday that its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial” Read at STAT ↗ Centre · 1VAX-31 is designed to protect against 31 serotypes of bacteria that can cause pneumococcal disease, including pneumonia, compared with 20 strains for Pfizer's Prevnar and 21 for Merck's Capvaxive. STATN “designed to protect against 31 serotypes, or strains, of bacteria that can cause pneumococcal disease, including pneumonia, compared to 20 strains for Pfizer’s Prevnar and 21 strains for Merck’s Capvaxive.” Read at STAT ↗ Centre · 1In the trial, just over 3,500 adults aged 50 and older were randomised to receive VAX-31, Prevnar or Capvaxive, and investigators measured the strength of their antibody responses against different strains. STATN “just over 3,500 adults age 50 and older were randomized to receive VAX-31, Prevnar, or Capvaxive” Read at STAT ↗
Right · 1According to IJR's account of the OPUS-1 topline results, VAX-31 met noninferiority on all 28 serotypes shared with Prevnar 20 and/or Capvaxive, and superiority on its three unique serotypes. IJRRC “It met noninferiority on all 28 serotypes shared with Prevnar 20 (PCV20) and/or Capvaxive (PCV21), superiority on its three unique serotypes” Read at IJR ↗ Right · 1The vaccine also showed a safety profile similar to those vaccines, IJR reported. IJRRC “a safety profile similar to those vaccines” Read at IJR ↗ Right · 1Grant Pickering of Vaxcyte said the result sets a new benchmark for the class and gives confidence in the vaccine's potential for approval. IJRRC “Grant Pickering said that sets a new benchmark for the class and gives confidence in its potential for approval.” Read at IJR ↗
Right · 1Results from the OPUS-2 and OPUS-3 trials are expected in the first half of 2027, with a Biologics License Application planned for the first half of 2028; VAX-31 is also in a Phase 2 infant program. IJRRC “OPUS-2 and OPUS-3 results are expected in the first half of 2027, with a Biologics License Application planned for the first half of 2028.” Read at IJR ↗ Right · 1IJR reported that shares closed Friday at $56.48, and that pre-market Monday prices were reported differently by MarketWatch ($92.67), MarketScreener ($94.50) and RTTNews ($71.00). IJRRC “Shares closed Friday at $56.48, up 0.77% and 22% year to date.”“$92.67 (MarketWatch), $94.50 (MarketScreener), or $71.00 (RTTNews)” Read at IJR ↗
Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.
Left0 outlets
No left outlet in our sources has covered this story yet.
Centre1 outlet
- Framing
- STAT frames the result as a challenge to Pfizer and Merck in a lucrative vaccine market, led by Vaxcyte's claim of success.
- Emphasis
- Competition with Pfizer and Merck, serotype counts and trial size.
- Charged language
- “claims success”“lucrative”
- For example
-
“Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market” — STAT
Right1 outlet
- Framing
- IJR reports the topline data in a company-results style, giving the endpoint details, Vaxcyte's executive quote, regulatory timeline and share-price data.
- Emphasis
- Serotype-level endpoint results, timeline to approval filing and stock prices.
- Charged language
- “new benchmark”
- For example
-
“Grant Pickering said that sets a new benchmark for the class and gives confidence in its potential for approval.” — IJR
What every side reports
- Vaxcyte said VAX-31 met the primary endpoints of a Phase 3 trial in adults.
- VAX-31 targets 31 pneumococcal serotypes, versus 20 for Pfizer's Prevnar and 21 for Merck's Capvaxive.
Where accounts differ
-
Vaxcyte's pre-market share price on Monday
- Right
- IJR said sources differed: $92.67 (MarketWatch), $94.50 (MarketScreener) or $71.00 (RTTNews).
Vaxcyte organisation
Says VAX-31 met its primary endpoints; CEO-level comment from Grant Pickering calls it a new benchmark for the class and says it gives confidence in approval.
“Grant Pickering said that sets a new benchmark for the class and gives confidence in its potential for approval.” — IJR
Left0 articles
No coverage yet.
Centre2 articles
-
STATN ·
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
Neutral Competitive-market angle: Vaxcyte's claimed success against Pfizer and Merck.
-
STATN ·
Right1 article
-
IJRRC ·
Vaxcyte to Present Topline Phase 3 Data for VAX-31 Vaccine
Neutral Data-focused results rundown with company quote, timeline and conflicting share-price figures.
- 4 Oct 22:04 First IJRRC Vaxcyte to Present Topline Phase 3 Data for VAX-31 Vaccine
- 5 Oct 13:19 +15h 15m STATN STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
- 5 Oct 14:10 +16h 5m STATN STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
Times are when each article was published, or when we first saw it if the outlet gave no time.